Malcolm Mason, MD
Prostate cancer survival was not significantly different among active monitoring, surgery, and radiotherapy for patients with prostate cancer, according to 10-year follow-up findings of the PROTECT study.
, Mason, a professor at the Institute of Cancer and Genetics, Cardiff University, discusses the significance of the 10-year follow-up of the PROTECT study for patients with prostate cancer and what it means for the field going forward.
OncLive: Please provide an overview of the PROTECT study for patients with prostate cancer.
Mason: The purpose of the PROTECT study was to directly test 3 major modalities of treatment for localized prostate cancer. The 3 modalities were external beam radiotherapy, radical prostatectomy, or deferred local treatment. Around the time this was set up 15 years ago, the terminology around deferred treatment was not settled. We now understand what active surveillance means. The term that was previously used was “active monitoring,” which was not the same since our protocols were different.
... to read the full story